Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap ConferenceGlobeNewsWire • 11/30/22
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell DiseaseGlobeNewsWire • 11/14/22
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/07/22
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/07/22
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual MeetingGlobeNewsWire • 11/03/22
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?Investors Business Daily • 10/20/22
Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B InfectionGlobeNewsWire • 09/19/22
Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare ConferenceGlobeNewsWire • 09/01/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMNewsfile Corp • 08/13/22
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/11/22
Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/09/22
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/08/22
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/04/22
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 08/03/22
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/03/22